Patents by Inventor Jennifer Maynard

Jennifer Maynard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CROSS-REACTIVE ANTIBODIES RECOGNIZING THE CORONAVIRUS SPIKE S2 DOMAIN
    Publication number: 20240294611
    Abstract: Provided herein are antibodies and antibody fragments that bind to the S2 domains of SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins. Methods of using these antibodies in in vitro methods are provided. Methods of using these antibodies in vivo to treat or prevent SARS-CoV-2 infections are also provided.
    Type: Application
    Filed: January 11, 2022
    Publication date: September 5, 2024
    Inventors: Jennifer MAYNARD, Yimin HUANG, Annalee NGUYEN, Ching-Lin HSIEH, Jason MCLELLAN, Rui P. SILVA, Edurado PADLAN
  • ENGINEERED CORONAVIRUS SPIKE (S) PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230242594
    Abstract: Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.
    Type: Application
    Filed: May 28, 2021
    Publication date: August 3, 2023
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Jason MCLELLAN, Jennifer MAYNARD, Andrea CHASSE, Ilya FINKELSTEIN, Mohammad JAVANMARDI, Jeffrey SCHAUB, Hung-Che KUO, Chia-Wei CHOU, Jory GOLDSMITH, Christy HJORTH, Ching-Lin HSIEH, Patrick BYRNE, Nicole JOHNSON, Nianshuang WANG, Daniel WRAPP
  • ANTI-MYOCILIN OLF ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230227541
    Abstract: Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the olfactomedin domain of myocilin Antibodies that can bind to natively folded myocilin, misfolded myocilin or both are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded and the neutralization and degradation of toxic misfolded myocilin from ex vivo samples or the eye.
    Type: Application
    Filed: May 24, 2021
    Publication date: July 20, 2023
    Inventors: Raquel L. Lieberman, Shannon E. Hill, Minh Thu Ma, Jennifer A. Maynard, Ahlam Qerqez, Laura Azouz Yuan
  • HIGH AFFINITY ENGINEERED T-CELL RECEPTORS TARGETING CMV INFECTED CELLS
    Publication number: 20220144916
    Abstract: Provided herein are engineered T-cell receptors (TCRs) having nanomolar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV/A2 presentation on the surface of cells.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 12, 2022
    Inventors: Jennifer A. MAYNARD, Ellen WAGNER, Ahlam N. QERQEZ, Annalee NGUYEN
  • ANTIBODIES THAT BIND TO NATIVELY FOLDED MYOCILIN
    Publication number: 20220026445
    Abstract: Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.
    Type: Application
    Filed: December 9, 2019
    Publication date: January 27, 2022
    Inventors: Raquel L. Lieberman, Shannon E. Hill, Athena Patterson-Orazem, Jennifer A. Maynard, Ahlam Qerqez, Laura Azouz Yuan
  • STABILIZED PERTUSSIS ANTIBODIES WITH EXTENDED HALF-LIFE
    Publication number: 20210332112
    Abstract: The present invention relates, in part, to modified humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed, in part, to improved humanized 1B7 and 11E6 antibodies with extended in vivo half-lives.
    Type: Application
    Filed: August 15, 2017
    Publication date: October 28, 2021
    Inventors: Jennifer MAYNARD, Annalee NGUYEN, Michael KALEKO
  • Bispecific pertussis antibodies
    Patent number: 10538579
    Abstract: The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: January 21, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer Maynard, Ellen Wagner
  • Humanized pertussis antibodies and used thereof
    Patent number: 10526400
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 7, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Engineered polypeptides for antigen delivery
    Patent number: 10450352
    Abstract: Recombinant high affinity Invasin polypeptide are provided herein. Further provided are methods of delivering therapeutics such as vaccines by conjugation to the engineered recombinant Invasin polypeptides.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 22, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer Maynard, Xianzhe Wang, Tarik Ali Khan
  • ENGINEERED POLYPEPTIDES FOR ANTIGEN DELIVERY
    Publication number: 20190106463
    Abstract: Recombinant high affinity Invasin polypeptide are provided herein. Further provided are methods of delivering therapeutics such as vaccines by conjugation to the engineered recombinant Invasin polypeptides.
    Type: Application
    Filed: March 23, 2017
    Publication date: April 11, 2019
    Inventors: Jennifer MAYNARD, Xianzhe WANG, Tarik Ali KHAN
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20180362621
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 20, 2018
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • BORDETELLA ADENYLATE CYCLASE TOXIN VACCINES AND NEUTRALIZING ANTIBODIES
    Publication number: 20180256699
    Abstract: The present disclosure describes immunogenic portions of Bordetella adenylate cyclase toxin (ACT), and neutralizing antibodies specific for such polypeptides. The antibodies can be used for diagnosis and anti-Bordetella therapies. Further provided are vaccine compositions including recombinant Bordetella adenylate cyclase toxin polypeptides.
    Type: Application
    Filed: December 8, 2015
    Publication date: September 13, 2018
    Inventors: Xianzhe WANG, Jennifer A. MAYNARD
  • Humanized pertussis antibodies and uses thereof
    Patent number: 10035846
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 31, 2018
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • BISPECIFIC PERTUSSIS ANTIBODIES
    Publication number: 20180118817
    Abstract: The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
    Type: Application
    Filed: August 15, 2017
    Publication date: May 3, 2018
    Inventors: Jennifer MAYNARD, Ellen WAGNER
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20170066816
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Humanized pertussis antibodies and uses thereof
    Patent number: 9512204
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 6, 2016
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20160304588
    Abstract: Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.
    Type: Application
    Filed: January 7, 2016
    Publication date: October 20, 2016
    Inventors: Jennifer A. Maynard, Jamie Sutherland
  • Pertussis antibodies and uses thereof
    Patent number: 9260510
    Abstract: Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 16, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jennifer A. Maynard, Jamie Sutherland
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20150353628
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: March 31, 2015
    Publication date: December 10, 2015
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan
  • PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20140193401
    Abstract: Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 10, 2014
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jennifer A. Maynard, Jamie Sutherland